Tirzepatide 10mg

Peptide Science research editorial team.

Tirzepatide 10mg Overview

Tirzepatide 10mg from Peptide Science is supplied as a lyophilised vial at 10 mg for in-vitro and preclinical adipose / metabolic research. Tirzepatide is a dual GLP-1 and GIP receptor agonist characterised in preclinical work for receptor-binding affinity and downstream incretin- or amylin-pathway signalling in pancreatic and adipose-tissue cell culture.

Receptor Profile and Class Background

Tirzepatide is a 39-amino-acid synthetic dual-agonist peptide engineered to bind both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor with high affinity. The dual-receptor profile makes it a research tool for studying incretin-pathway crosstalk in cultured pancreatic beta-cells and adipocytes, where single-receptor agonists like Semaglutide cannot replicate the combined signal integration. The peptide includes a C20 fatty-diacid side chain that supports the same albumin-binding extended-stability mechanism seen in Semaglutide. Browse the broader metabolic peptide research range for adjacent compounds.

Specifications

For lower or higher strength variants, see Tirzepatide 5mg and Tirzepatide 15mg.

Reconstitution and Handling

The lyophilised vial reconstitutes with bacteriostatic water at the working concentration set by the principal investigator. Material is sensitive to repeated freeze-thaw cycles; aliquoting reconstituted stock for single-use frozen storage is the standard preclinical handling practice cited in incretin-research literature.

Quality and Shipping

Each batch passes HPLC at greater than 99 percent purity, with mass-spectrometry identity confirmation against the theoretical mass. A Certificate of Analysis accompanies every order. Material is filled in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in temperature-monitored insulated packaging via overnight or two-day courier.

For laboratory research and development use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease, including obesity or type 2 diabetes. Has not been evaluated by the U.S. Food and Drug Administration. Branded therapeutic GLP-1, GIP, and dual-agonist medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription-only medicines in the United States and are not the same as research-grade compounds supplied for in-vitro work. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws.